Market Intelligence, Preclinical Progress, and High-Purity Reagents for Ribosomal Targeting, DNA Damage Response, and Selectivity Screening.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for RPL3 drug discovery and functional validation.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RPL3 Recombinant Protein (Wild-Type & Mutant Variants). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. | View RPL3 Products |
| Gene Delivery | RPL3 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines, overexpression, or dominant-negative studies. | View RPL3 Products |
| Benchmark Ab | Anti-RPL3 Polyclonal Antibody. Recombinant positive control for Western Blot and IF. | View RPL3 Products |
| Validator | RPL3 siRNA Set (Triple Targeting). For knockdown verification, functional rescue assays, and specificity checks. | View RPL3 Products |
| Related Target | RPL11. Ribosomal stress pathway component; MDM2/p53 axis synergy. | View RPL11 Products |
| Related Target | RPL5. 60S subunit neighbor; critical for ribosome assembly and selectivity profiling. | View RPL5 Products |
| Related Target | MDM2. Direct binding partner of RPL3; E3 ubiquitin ligase complex component. | View MDM2 Products |
| Related Target | TP53 (p53). Downstream effector stabilized by RPL3; DNA damage response pathway. | View TP53 Products |
| Related Target | PRKDC (DNA-PKcs). DNA repair kinase associated with RPL3 in DSB response. | View PRKDC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Species selectivity (Human vs. Bacterial L3) | Human RPL3 & Bacterial L3 ortholog proteins available with >95% purity; Sequence Verified |
| Ribosomal protein subfamily cross-reactivity | Homolog panel (RPL3, RPL3L, RPL11, RPL5) strictly verified by mass spec |
| Intracellular target specificity | High Purity (>95%) recombinant proteins with native folding for SPR/BLI binding assays |
| Cellular pathway disruption (RPL3-MDM2/DNA-PKcs) | Full-length ORF lentivirus enabling precise stable cell line generation and epitope-tagged expression |
| Lack of Controls | Functional-grade siRNA, Benchmark Antibodies, and ORF-tagged Lentivirus included |
| False Positives in Screening | Validated siRNA and sequence-verified shRNA vectors for specificity checks |
| Mutant variants in chemoresistance models (e.g., cisplatin) | Site-specific mutant recombinant proteins with mass spec verification |
Global Clinical Landscape & Future Outlook
Research into ribosomal protein targeting is expanding from antibiotics to oncology, where modulating ribosomal stress represents a nascent therapeutic axis. RPL3 (Ribosomal Protein L3) is an intracellular ribosomal protein with extraribosomal functions, particularly in DNA damage response (DDR) and p53 stabilization via MDM2 interaction. The current pipeline is predominantly early discovery and preclinical, with academic consortia and early biotech companies exploring its role in drug resistance (e.g., cisplatin/5-FU resistance in gastric/colorectal cancer) and nucleolar stress pathways. Major R&D directions include: (1) siRNA-based chemosensitization strategies; (2) small molecule PPI inhibitors disrupting RPL3-MDM2; (3) PROTACs for targeted degradation of overexpressed RPL3; and (4) gene therapy for ribosomopathies. As bacterial L3 inhibitors face resistance pressure, demand for high-fidelity human RPL3 counter-screening reagents is rising simultaneously.
Key Mutation and Disease Context
UniProt and clinical genetics databases have documented a missense mutation in RPL3 (dbSNP: rs1569) found in a Diamond-Blackfan anemia (DBA) patient. The clinical significance is uncertain but highlights the involvement of RPL3 in ribosome biogenesis disorders. This variant underscores the need for wild-type and mutant recombinant proteins in mechanistic studies of ribosomopathies and potential drug resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Selectivity/PPI) | Antimicrobial Discovery, Preclinical Biotech | Bacterial Infections, Solid Tumors, Chemoresistance | Human RPL3 counter-screen & binding assays (need high-purity human vs bacterial ortholog) |
| PROTAC / Degrader | Emerging Targeted Degrader Co. | Refractory Cancers | Degradation validation (need specific knockdown/siRNA controls) |
| siRNA / shRNA | Academic Consortia, Early Biotech | Gastric, Colorectal Cancer (Resistance) | Knockdown efficiency validation (need validated siRNA sets & Lentivirus) |
| Antimicrobial (Bacterial L3) | Antibiotic Discovery Programs | Bacterial Infections | Ortholog specificity screening (need bacterial vs. Human RPL3 comparison) |
| Gene Therapy (Overexpression) | Preclinical Gene Therapy | Ribosomopathies, Chemoprotection | Expression validation (need ORF Lentivirus with high titer) |
| Functional Genomics | Academic & Industry Consortia | Cancer Biology | Stable knockdown/overexpression (need Lentivirus & siRNA) |